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Abstract Several neural, hormonal and biochemical inputs ac-
tively participate in the balance of insulin secretion induced by
blood glucose £uctuations. The exact role of insulin as an auto-
crine and paracrine participant in the control of its own secre-
tion remains to be determined, mostly due to insu⁄cient knowl-
edge about the molecular phenomena that govern insulin
signaling in pancreatic islets. In the present experiments we
demonstrate that higher insulin receptor and insulin receptor
substrates-1 and -2 (IRS1 and IRS2) concentrations are pre-
dominantly encountered in cells of the periphery of rat pancre-
atic islets, as compared to centrally located cells, and that
partial blockade of IRS1 protein expression by antisense
oligonucleotide treatment leads to improved insulin secretion
induced by glucose overload, which is accompanied by lower
steady-state glucagon secretion and blunted glucose-induced glu-
cagon fall. These data reinforce the inhibitory role of insulin
upon its own secretion in isolated, undisrupted pancreatic islets.
& 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Following the demonstration of the presence of insulin re-
ceptor (IR) and its main substrates, insulin receptor substrate-
1 and -2 (IRS1 and IRS2, respectively) in pancreatic islets
[1^3], a series of studies have attempted to characterize the
molecular events that link insulin to the autocrine control of
its own secretion. In that respect, the generation of mice car-
rying targeted disruption of the genes encoding for proteins
participating in insulin signaling has been rather elucidating.
Spontaneous mutations leading to whole body ablation of the
IR leads to severe insulin resistance and neonatal death in
both humans and animals [4]. Homozygous targeted disrup-
tion of the IR in the whole body promotes hyperinsulinemia
and insulin resistance, leading to severe ketosis and death
within few days [5]. However, heterozygous IR disruption
produces a mild phenotype with only 10% of animals devel-
oping diabetes at later stages of life [6]. The disruption of IR
speci¢cally in pancreatic L cells using the Cre-lox system
under the control of the insulin promoter leads to a progres-
sive loss in glucose-induced ¢rst-phase insulin secretion, de-
creased islet volume and insulin content, and age-dependent
glucose intolerance [7]. Genetic manipulation of the main sub-
strates of the IR o¡ered further information on the role of
insulin upon the control of L cell function. Thus, IRS1 whole
body knockout produces growth retardation accompanied by
islet hyperplasia and increased insulin secretion [8,9], while
IRS2 whole body knockout leads to severe insulin resistance,
L cell hypoplasia with decreased insulin secretion and early-
onset diabetes [10].
In isolated L cells IRS1 participates in the control of insulin
secretion through a mechanism that involves the lipid metab-
olizing enzyme phosphatidylinositol 3-kinase (PI3-kinase) and
the mobilization of Caþ2 [11^14]. On the other hand, IRS2
expression in L cells seems to be involved in the control of cell
growth and mitogenesis [15,16].
According to the current concepts a paradigm has been
generated proposing that, once secreted by pancreatic L cells,
insulin acts upon an autocrine loop activating L cell IRs that
lead to IRS1 engagement and further enhancement of insulin
secretion through a Caþ2-dependent mechanism [11]. Through
the same autocrine loop insulin (probably to a lesser extent
than IGF-1) activates IRS2, which participates in the control
of L cell growth and mitogenesis, most probably during early
phases of development or in L cell tumorigenesis [7,16,17], or
yet, in the induction of transcription of genes that encode
proteins that participate in the physiologic control of L cell
function [18].
Ancient studies by Mallaise and his collaborators [19] and
recent data [20] indicate that exposure of isolated pancreatic
islets to insulin leads to reduced rather than increased insulin
secretion. Thus, it seems that when acting upon an undis-
rupted and non-genetically manipulated pancreatic islet, insu-
lin provides a signal that, through unknown mechanisms, pro-
duces a net e¡ect that is inhibitory on its own secretion. In the
present study, evidence is provided which indicates that so-
matostatin and glucagon, secreted under the control of insu-
lin, participate in the paracrine control of insulin secretion,
and that paracrine signaling in pancreatic islets provide a
more robust signal than the autocrine signal of insulin.
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2. Materials and methods
2.1. Antibodies, chemicals and bu¡ers
Antibodies against IRL (SC-711), IRS1 (SC-560), IRS2 (SC-1556),
somatostatin (SC-7819), and glucagon (SC-7779) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against rat
insulin (guinea pig raised) were a kind donation of Dr Leclerq-Meyer
(Free University of Brussels, Belgium). Antibodies against phospho-
tyrosine (py; #05-321) were from UBI (Lake Placid, NY, USA). So-
matostatin and glucagon RIA kits were from Phoenix Pharmaceuti-
cals (Belmont, CA, USA) and Linco Research (St. Charles, MI,
USA), respectively; insulin was determined by RIA. 125I-protein A
Sepharose and 125I-insulin were from Amersham (Buckinghamshire,
UK). Protein A Sepharose 6MB was from Pharmacia (Uppsala, Swe-
den). All the remaining chemicals used in the experiments were from
Sigma (St. Louis, MO, USA). Bu¡er A used in immunoblotting ex-
periments consisted of 100 mM Tris, 10 g/l SDS, 50 mM HEPES (pH
7.4), 100 mM sodium pyrophosphate, 100 mM sodium £uoride, 10
mM EDTA, 10 mM sodium vanadate, 2 mM PMSF and 0.1 mg/ml
aprotinin. Krebs^bicarbonate bu¡er equilibrated with 95% O2 :5%
CO2, pH 7.4, was used in islet isolation and contained either 2.8
mM or 16.7 mM glucose.
2.2. Phosphorthioate-modi¢ed oligonucleotides
Sense and antisense phosphorthioate oligonucleotide speci¢c for
IRS1 (sense, 5P ACC CAC TCC TAT CCC G 3P and antisense,
5P CGG GAT AGG AGT GGG T 3P) were produced by Invitrogen
(Carlsbad, CA, USA). This sequence was selected among three unre-
lated pairs of oligonucleotides on the basis of their ability to block
IRS1 protein expression as evaluated by immunoblot of total protein
extracts of isolated pancreatic islets utilizing speci¢c anti-IRS1 anti-
bodies.
2.3. Experimental animals and islet isolation
All experiments were performed with male Wistar rats (240^260 g)
from the University of Campinas Breeding Center. For islet isolation
the rats were anesthetized by intraperitoneal injection of sodium-amo-
barbital (15 mg/kg body weight) and, following the loss of corneal and
pedal re£exes, the animals were killed by decapitation. The abdominal
cavity was rapidly opened and the pancreatic duct was cannulated for
collagenase infusion. The pancreas was then removed and submitted
to collagenase digestion. Islets were isolated by careful handpicking,
following a method previously described [21]. The University of Cam-
pinas Ethical Committee approved all experiments.
2.4. Immunohistochemistry
Pancreata obtained from six rats were examined to determine the
expression and tissue distribution of proteins that participate in in-
sulin signaling. Hydrated, 5-Wm sections of paraformaldehyde-¢xed,
para⁄n-embedded tissue were stained by the avidin-peroxidase and
single or double-staining £uorescence methods. Sections were incuba-
ted for 30 min with 2% normal rabbit, normal goat or normal mouse
sera at room temperature, and then exposed for 12 h in moister
chamber at 4%‡C to the primary antibodies against IRL (1/20),
IRS1 (1/50), IRS2 (1/50), glucagon (1/50), somatostatin (1/20), or in-
sulin (1/50). For the avidin-peroxidase method, biotinylated secondary
antibodies were used in incubations for 2 h at room temperature,
which were followed by 1 h incubation with ready-to-use avidin-
coupled peroxidase from Vector. The resulting immunocomplexes
were detected with 50 mg/100 ml diaminobenzidine ^ 4 M HCl/0.01
ml/100 ml H2O2 dissolved in 5 mM Tris, pH 7.6. For single or double
immuno£uorescence staining, FITC and rhodamine-conjugated sec-
ondary antibodies were employed and analysis and photo-documen-
tation were performed using an Olympus BX60 Microscope and a
Zeiss LSM 510 Laser Scanning Confocal Microscope.
2.5. Static secretion studies
Groups of ¢ve freshly isolated islets were initially incubated for 6 h
at 37‡C in RPMI 2.8 mM glucose with no oligonucleotide, or in the
presence of either 4 nM sense or 4 nM antisense IRS1 oligonucleotide.
RPMI was then replaced and islets were maintained for 1 h under the
experimental conditions (RPMI containing 2.8 mM, 11 mM or 16.7
mM glucose, with either no oligonucleotide addition or in the pres-
ence of sense or antisense IRS1 oligonucleotide). At the end of incu-
bation time samples of the supernatants of the incubation medium
were collected for hormone measurement.
2.6. Dynamic secretion studies
Groups of 100 freshly isolated islets were pre-incubated during 6 h
at 37‡C in RPMI 2.8 mM glucose with no oligonucleotide or in the
presence of either 4 nM sense or 4 nM antisense IRS1 oligonucleotide.
Thereafter the islets were placed on a Millipore SW 1300 ¢lter (8-Wm
pore) in a perfusion chamber. Islets were continuously perfused at a
£ow rate of 1 ml/min. During the initial 20 min of perfusion the bu¡er
consisted of Krebs^bicarbonate solution containing 2.8 mM glucose
(maintaining the presence or not of respective oligonucleotides in
perfusion solution). Finally, a perfusion bu¡er containing 11 mM or
16.7 mM glucose was introduced and the presence or absence of
respective oligonucleotides was maintained. Samples of perfusate for
quanti¢cation of insulin were collected at every second minute, start-
ing at the tenth minute following the beginning of perfusion.
2.7. Immunoblot, immunoprecipitation and PI3-kinase activity analysis
For speci¢c protein determination groups of 300 freshly isolated
islets were incubated for 6 h in RPMI containing 2.8 mM glucose
in the presence of 4 nM sense or antisense IRS1 oligonucleotide or
with no addition of oligonucleotide. Following incubation, islets were
lysed in 0.3 ml of boiling bu¡er A and insoluble material was removed
by centrifugation during 20 min at 12 000Ug. Protein extracts from
skeletal muscle, adipose tissue and liver were obtained as previously
described [22]. Protein quanti¢cation in the supernatants was deter-
mined by the Bradford method [23]. Samples containing 0.2 mg total
proteins were separated by SDS^PAGE, transferred to nitrocellulose
membranes and blotted with speci¢c antibodies. For immunoprecipi-
tation followed by immunoblot analysis and for IRS1-associated PI3-
kinase activity assays, groups of 800 pancreatic islets were exposed to
experimental conditions and technical procedures were performed as
previously described [24]. Visualization of speci¢c protein bands was
performed by incubating membranes with 125I-protein A followed by
exposure to RX-¢lms. For PIP evaluation in PI3-kinase assays TLC
plates were exposed to RX-¢lms.
2.8. Semi-quantitative analysis of somatostatin mRNA
Groups of islets were cultured for 12 h at 37‡C in RPMI 1640
medium containing 5.6 mM glucose and 5% FCS. Insulin 1036 M
(insulin concentration within the pancreatic islet microenvironment
of living animals is believed to oscillate between 1039 and 1037 M
in fasting and fed conditions, respectively) [11,25,26], sense or anti-
sense IRS1 phosphorthioate-modi¢ed oligonucleotide were added as
required. To determine the expression level of glucagon, insulin and
somatostatin mRNA, the relative amount of respective products ob-
tained by reverse transcription PCR (RT-PCR) was compared to
L-actin mRNA. Total cellular RNA was extracted from groups of
500 islets using Trizol reagent (Invitrogen). Reverse transcription
was performed on 1 Wg total RNA using Moloney murine leukemia
virus-reverse transcriptase (Superscript II) and random hexamers ac-
cording to manufacturer instructions (Invitrogen). RT-PCR assays
were performed using Taq DNA polymerase, recombinant (Invitro-
gen) containing 10 pmol of each primer in a master mix of 50 Wl. PCR
primers for rat glucagon (forward, 5P CGC CAG ATC ATT CCC
AGC TTC C 3P ; reverse, 5P CGC CCA AGT TCC TCA GCT ATG
G 3P) amplify a 345-bp cDNA fragment, for rat somatostatin (for-
ward, 5P ACC GGG AAA CAG GAA CTG GC 3P ; reverse, 5P TGG
GAT TTG GAG GAG AGG GAT C 3P) amplify a 277-bp cDNA
fragment, for rat insulin (forward, 5P ATT GTT CCA ACA TGG
CCC TGT 3P ; reverse, 5P TTG CAG TAG TTC TCC AGT T 3P)
amplify a 340-bp cDNA fragment, and for rat L-actin (forward,
5P ATG AAG ATC CTG ACC GAG CGT G 3P ; reverse, 5P CTT
GCT GAT CCA CAT CTG CTG G 3P) amplify a 510-bp cDNA
fragment. PCR ampli¢cation conditions were 2 min at 95‡C, followed
by cycles of 95‡C for 30 s, 58‡C for 30 s, and 72‡C for 30 s. The
number of cycles were 26 for L-actin, glucagon and insulin, and 32 for
somatostatin. Cycle numbers were de¢ned after titration between 20
and 42 cycles and were within the logarithmic phase of ampli¢cation.
PCR samples were submitted to electrophoresis down a 2% agarose
gel, and DNA was visualized by ethidium bromide staining. The band
intensities were determined by digital scanning, followed by quanti¢-
cation using Scion Image analysis software.
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2.9. Statistical analysis
Speci¢c protein bands present in the blots or PIP dots in TLC
plates were quanti¢ed by densitometry. Mean values W S.E.M. ob-
tained from densitometric scans, and values for insulin, glucagon
and somatostatin during static secretion studies were compared utiliz-
ing Turkey^Kramer test (ANOVA). Insulin quanti¢cations during
dynamic secretion studies were compared after log-transformation in
order to correct for variance heterogeneity or non-normality utilizing
Turkey^Kramer test (ANOVA). A P6 0.05 was accepted as statisti-
cally signi¢cant.
3. Results and discussion
Since the ¢rst observation of IR, IRS1 and IRS2 expression
in pancreatic islets no further progression was achieved on the
characterization of the cellular distribution of such elements
in endocrine pancreas [1^3]. In the presence of compelling
evidence about the inhibitory role of insulin upon its own
secretion [19,20] we decided to perform a thorough evaluation
of tissue distribution of the participants of the insulin-signal-
ing pathway in sections of pancreas obtained from 8 to 12-
week-old Wistar rats, and to investigate the integration of the
molecular events triggered by insulin and the functional re-
sponse to that hormone in undisrupted, genetically non-ma-
nipulated pancreatic islets. Using antibodies speci¢c for IR,
IRS1, IRS2, insulin, glucagon and somatostatin, and utilizing
an array of immunohistochemical methods, a full character-
ization of the tissue distribution of each of the elements that
participate in the early steps of insulin signaling in pancreatic
islets was obtained. IR is expressed in all cell types of the islet.
However, there is a clear di¡erence in the patterns of expres-
sion of the protein when comparing cells from the core of the
islets with cells at the periphery (Figs. 1a,d, 2g). A series of
double-staining immunohistochemical studies utilizing anti-
bodies against IR in conjunction with either insulin, glucagon
or somatostatin antibodies, allowed for mapping the expres-
sion of IR predominantly to somatostatin producing cells,
however some co-localization with glucagon was detected
(Fig. 2g^i). The characteristics of IRS1 expression in rat pan-
creatic islets are the same as for IR. Thus, IRS1 is widely
expressed in pancreatic islets (Fig. 1b,e), and employing dou-
ble stain technique evaluated by conventional and confocal
microscopy most of the expression was revealed to occur in
N cells (Fig. 2a^c). Finally and similarly, IRS2 is present in all
cells of the islets with highest expression occurring at the
periphery (Fig. 1c,f) and depicting an impressive co-localiza-
tion with somatostatin (Fig. 2d^f). Therefore, based on the
characteristics of tissue distribution of IR and its substrates, it
is suggested that both autocrine and paracrine signaling of
insulin shall play a role in whole islet function. Since all stud-
ies on which proteins of the insulin-signaling pathway were
knocked out were undertaken in mice, we performed immu-
nohistochemical evaluation of IR, IRS1 and IRS2 in pancreas
of CBA/J mice and detected a similar pattern of speci¢c pro-
tein distribution as in rat islets (not shown).
Supported by evidence that IRS1 participates in the control
of insulin secretion through PI3-kinase-modulated Caþ2 in£ux
[13,14], and that IRS2 may be more importantly related to cell
growth and mitogenesis [15], we decided for evaluating the
role of IRS1 in autocrine and paracrine insulin signaling by
blocking IRS1 protein synthesis utilizing phosphorthioate-
modi¢ed antisense oligonucleotides speci¢c for IRS1. Islet
speci¢c expression of IR and IRS1 is approximately 0.3-fold
that observed in tissues that traditionally respond to insulin
stimulus, such as liver, adipose tissue and skeletal muscle (Fig.
3a,b). Nonetheless, the exposure of isolated islets to either
1036 M insulin or 16.7 mM glucose produces e¡ects that
are similar to those observed in liver, muscle and fat when
IR IRS1 
a. b. c.
d. e. f.
Fig. 1. Immunohistochemical characterization of tissue distribution
of proteins that participate in insulin signaling in pancreatic islets of
rats. a: IR single staining detected by immunoperoxidase; b: IRS1
single staining detected by immunoperoxidase; c: IRS2 single stain-
ing detected by immunoperoxidase; d: IR single staining detected
by FITC-labeled immuno£uorescence; e: IRS1 single staining de-
tected by FITC-labeled immuno£uorescence; f : IRS2 single staining
detected by FITC-labeled immuno£uorescence. The expression of IR
(a and d) occurs widely in pancreatic islets with apparent higher ex-
pression in cells of the periphery (arrows in a and d). The same pat-
tern of IR expression is observed in single-primary antibody IRS1
and IRS2 staining (b and e, c and f, respectively), with arrows de-
picting the preferential peripheral expression.
Fig. 2. Double immuno£uorescence staining for IRS1 and somato-
statin (a^c); IRS2 and somatostatin (d^f); and IR and glucagon
(g^i). Note that both IRS1 and IRS2 are widely distributed in islet
cells; however, there is a clear preferential co-localization with so-
matostatin (c and f). IR is, as well, widely distributed in pancreatic
islets, and some cells clearly stain for both IR and glucagon (g^i).
In the inset in h the granules of glucagon are apparent in a cell ex-
pressing IR.
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living animals are challenged by insulin. Thus, increases of 2.0
and 2.5-fold in IR (P6 0.05) and IRS1 (P6 0.05) tyrosine
phosphorylation, respectively, are induced after 90 s islet ex-
posure to 1036 M insulin (Fig. 3c,d). Exposure of islets to
high glucose concentration (16.7 mM) for 3 min also induced
signi¢cant increase in IR and IRS1 tyrosine phosphorylation
(Fig. 3c,d). The e¡ect of glucose upon the activation of ele-
ments participating in insulin-signaling pathway seems to be
mediated by secreted insulin, since it is blunted if isolated
islets are incubated in the presence of 100 WM diazoxide
(Fig. 3c,d). Following insulin-stimulated phosphorylation of
IR and IRS1 a series of intracellular branches of the insu-
lin-signaling cascade may be induced. Among them the mod-
ulation of the activity of the lipid metabolizing enzyme PI3-
kinase seems to play a particularly important role in the con-
trol of insulin secretion [27^29]. Once activated PI3-kinase
catalyzes the incorporation of phosphate at the 3P position
of membrane-bound phosphoinositols generating PI3,4P2
and PI3,4,5P3, which serve as docking sites for downstream
signaling molecules, and for connecting the insulin signal with
stimuli delivered by other hormones, growth factors and cy-
tokines [30]. Exposure of isolated islets to 1036 M insulin for
5 min induces a signi¢cant increase (1.7-fold, P6 0.05) in
IRS1-associated PI3-kinase activity (Fig. 3e), reproducing in
that way the characteristics of the molecular response to in-
sulin observed in traditional target tissues.
In order to evaluate the property of phosphorthioate-modi-
¢ed oligonucleotides antisense to block IRS1 protein synthe-
sis, three di¡erent sequences were tested. Groups of 300 islets
were incubated in RPMI containing 2.8 mM glucose in the
presence of 4 nM sense or antisense oligonucleotides or in the
absence of oligonucleotides. Incubation times were either 3 h
or 6 h. Based on the results obtained, the sequence 5P CGG
GAT AGG AGT GGG T 3P for antisense IRS1 and its re-
spective sense were selected for the studies. Six hours incuba-
tion in the presence of the selected antisense oligonucleotide
was su⁄cient to promote 45% reduction in IRS1 expression in
isolated islets (Fig. 4a) and was utilized as standard pre-incu-
bation time in all experiments.
Fig. 3. The expression of IR (a) and IRS1 (b) is quantitatively com-
pared in islets (ISL), skeletal muscle (SM), white adipose tissue
(WAT) and liver (LIV) of rats. Two hundred Wg of total protein ex-
tracts from each tissue were separated by SDS^PAGE, transferred
to nitrocellulose membranes and blotted (ib) with anti-IR (a) or
anti-IRS1 (b) antibodies. Islets express between 0.2 and 0.3-fold of
IR (n=4, *P6 0.05 as compared to SM, WAT and LIV), and 0.2
and 0.3-fold of IRS1 (n=4, *P6 0.05 as compared to SM, WAT
and LIV) of the respective amounts expressed by tissues that are
traditional targets for insulin action. Tyrosine phosphorylation of
IR and IRS1 is evaluated by immunoprecipitation (ip) of pancreatic
islet protein extracts with anti-IR (c) and anti-IRS1 (d) antibodies,
and immunoblotting (ib) with anti-phosphotyrosine (py) antibodies.
Insulin and high glucose (16.7 mM) promoted signi¢cant induction
of tyrosine phosphorylation of IR (c) (n=4, *P6 0.05, as compared
to islets maintained in 2.8 mM glucose) and IRS1 (d) (n=4,
*P6 0.05, as compared to islets maintained in 2.8 mM glucose),
while diazoxide (Diaz) was capable of impairing high glucose-in-
duced IR (c) or IRS1 (d) tyrosine phosphorylation. Insulin induces
the activation of IRS1-associated PI3-kinase (e). Immunoprecipitates
collected from protein extracts obtained from control (2.8 mM glu-
cose) and insulin-treated isolated islets were assayed for PI3-kinase
activity and analyzed following TLC resolution. The exposure of
isolated islets to 1036 M insulin induces an increase of 1.7-fold in
IRS1-associated PI3-kinase activity (n=3, *P6 0.05). PIP, phos-
phorylated phosphoinositol.
Fig. 4. Treatment of isolated islets with phosphorthioate antisense
IRS1 oligonucleotide promotes a reduction of 40% in protein ex-
pression of IRS1 (a) (n=4, *P6 0.05, as compared with islets non-
exposed to antisense oligonucleotide) as detected by immunoblot
(ib) performed on nitrocellulose transfers of SDS^PAGE separations
of 0.2 mg total protein extracts from islets treated with 4 nM sense
(S IRS1) or antisense (AS IRS1) oligonucleotide, or exposed to no
oligonucleotide (WO IRS1). In static insulin secretion studies (b), a
signi¢cant increase in glucose-stimulated insulin secretion is detected
in islets treated with IRS1 antisense oligonucleotide (AS) [n=5,
*P6 0.05, as compared with islets not exposed to oligonucleotides
(WO)]. The values 2.8 mM, 11 mM and 16.7 mM refer to the con-
centration of glucose in incubation media and S refers to IRS1
sense oligonucleotide treated islets. During dynamic secretion studies
(c and d), signi¢cant rise in the rate of glucose-induced insulin se-
cretion is detected in islets exposed to IRS1 antisense oligonucleoti-
des and submitted to either 11 mM (c) or 16.7 mM (d) glucose con-
centration (n=5, *P6 0.05, when comparing IRS1 oligonucleotide
antisense treated islets with islets exposed to no oligonucleotide).
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In static insulin secretion studies, the treatment of isolated
islets with antisense oligonucleotide promoted no signi¢cant
change in the rate of insulin secretion of islets incubated in 2.8
mM glucose (Fig. 4b). However, when islets were exposed to
high glucose concentrations (11 mM or 16.7 mM), signi¢cant
increases in glucose-induced insulin secretion were observed
(2.0 and 2.8-fold, respectively, P6 0.05; Fig. 4b). No changes
in insulin secretion were promoted by exposure of islets to
IRS1 sense oligonucleotide (Fig. 4b). Similarly, during dy-
namic insulin secretion studies the blockade of IRS1 expres-
sion was accompanied by a signi¢cant increase in glucose-
induced insulin secretion both when islets were exposed to a
medium containing 11 mM or 16.7 mM glucose (Fig. 4c,d,
respectively). Of particular interest, it was observed that treat-
ment with antisense IRS1 oligonucleotide coincided with a
reduction of insulin secretion rate in islets exposed to 2.8
mM glucose, and that the increased rate of insulin secretion
under high glucose condition was more pronounced after 15
min of 11 mM or 16.7 mM glucose exposure (Fig. 4c,d),
which might suggest that intermediary steps in signaling shall
participate in the observed phenomenon. Determination of
insulin-induced insulin mRNA expression in pancreatic islets
showed that exposure of isolated islets to exogenous insulin at
a concentration of 1036 M for 6 h produces a signi¢cant
decrease (0.65-fold, n=4; P6 0.05, as compared to islets
maintained in 2.8 mM glucose without exogenous insulin) in
insulin mRNA species, while blockade of IRS1 expression by
antisense oligonucleotide treatment for 6 h preceding and dur-
ing exogenous insulin treatment could partially inhibit the
capacity of exogenous insulin to negatively modulate insulin
mRNA expression (0.9-fold, n=4; n.s. vs. islets maintained in
2.8 mM glucose without exogenous insulin).
Since higher expression levels of IR and IRS1 were detected
in cells located at the periphery of the islets (mostly in N cells),
we decided to investigate the role of IRS1 blockade upon the
pattern of secretion of glucagon and somatostatin in isolated
islets exposed to low (2.8 mM) or high (16.7 mM) glucose
concentrations. Although insulin is known to enhance the in-
hibitory e¡ect of glucose upon glucagon secretion [31], the
mechanisms responsible for the isolated e¡ect of insulin
upon K cells is controversial. It is well-known that insulin
increases the content of ATP in K cells [32], and that patients
and animal models with insulin-de¢cient diabetes mellitus
present a blunted suppression of glucagon secretion, such as
they are relatively or absolutely hyperglucagonemics [33,34].
Thus insulin may act directly upon K cells participating in the
¢ne control of glucagon secretion. Previous attempts to char-
acterize the presence of IR or functional binding sites for
insulin in K cells were not successful [35], and in the present
series of experiments we were also unable to provide undis-
puted evidence for that fact. However, the pattern of staining
for IR, IRS1 and IRS2 observed in more than 60 di¡erent
sections evaluated during these studies (Fig. 2g^i), plus the
characteristics of glucagon secretion in IRS1 depleted islet
(Fig. 5a) and the modulation of glucagon mRNA expression
in the presence of exogenous insulin and under the blockade
of IRS1 (Fig. 5c) strongly suggest that IR is present and func-
tional in glucagon-secreting cells.
Similarly to the control of glucagon secretion, the e¡ects of
glucose and insulin upon somatostatin release are not com-
pletely understood. Most studies to date provide evidence for
glucose-induced inhibition of somatostatin release [31], while
only a few studies have attempted to characterize the e¡ects of
insulin upon its secretion. In most of those studies no signi¢-
cant modulation inputted by insulin was detected [36,37]. In
the present studies the blockade of IRS1 promoted no signi¢-
cant changes in the rate of somatostatin secretion under either
low or high glucose concentrations (Fig. 5b). Nevertheless, the
partial blockade of IRS1 protein expression promoted a sig-
ni¢cant fall in somatostatin mRNA expression in pancreatic
islets (Fig. 5d). Since the secretion amounts of somatostatin in
isolated islets are extremely low, the detectability of tradition-
al RIAs to estimate subtle variations in hormone secretion
may be not optimal. The present results suggest that insulin,
by acting through IRS1, may stimulate somatostatin mRNA
expression and possibly participate in the control of the N
cell’s hormone secretion.
As a whole the present studies provide evidence that the
blockade of IRS1 expression promotes signi¢cant increase in
glucose-induced insulin secretion. As most studies to date
have evidenced a stimulatory role of insulin upon its own
secretion in isolated L cells [13,14,38], we suspect that the
phenomenon reported herein might be due to paracrine inter-
actions between K, L and N cells within the islets. Based on
that, a model for explaining the participation of IRS1 on
paracrine and autocrine insulin signaling, and the functional
feedback exerted by glucagon and possibly by somatostatin, is
presented (Fig. 6). Under steady-state low glucose concentra-
tion, high glucagon and low somatostatin secretions accom-
pany a low basal rate of insulin secretion. Once exposed to
increased glucose concentration the rate of insulin secretion is
Fig. 5. Static glucagon (a) and somatostatin (b) secretion studies,
and glucagon (c) and somatostatin (d) mRNA expression evaluated
by RT-PCR. A signi¢cant fall in steady-state glucagon (a) secretion
is induced by IRS1 antisense oligonucleotide (AS) treatment [n=4,
*P6 0.05, as compared with islets exposed to no oligonucleotides
(WO)]. No signi¢cant variation of somatostatin (b) secretion is de-
tected by the present method (n=4). For a and b, 2.8 mM and 16.7
mM correspond to glucose concentrations in incubation media, anti-
sense (AS), sense (S) and no oligonucleotide treatment (WO). In c,
treatment with IRS1 antisense (AS) oligonucleotide induced a signif-
icant fall in glucagon mRNA expression, which tended to increase
under the stimulus of exogenous insulin (n=5, *P6 0.05, as com-
pared with islets exposed to no oligonucleotides). In d, treatment
with IRS1 antisense (AS) oligonucleotide induced a signi¢cant fall
in somatostatin mRNA expression in islets maintained either in cul-
ture media with low glucose (2.8 mM) or in the presence of 1036 M
insulin (Ins) (n=5, *P6 0.05 as compared with islets exposed to no
oligonucleotides). Sense oligonucleotides exerted no e¡ect upon glu-
cagon and somatostatin mRNA expression (not shown).
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promptly stimulated and acts in concert with glucose to blunt
glucagon release and possibly to promote a discrete increase
in somatostatin secretion. The reduced tonus of glucagon and
increased microenvironment concentration of somatostatin
may play an important role in ¢ne control of glucose-induced
insulin secretion. When glucose levels start to fall the tonus
provided by the combination of low-glucagon^high-somato-
statin might accelerate insulin-secretion-rate reduction. Ham-
pering of insulin signaling in pancreatic islets by blocking
IRS1 expression leads to a L cell inhibitory e¡ect, which is
apparently overcome by a more robust signal of reduced so-
matostatin accompanied by an inversion in the pattern of
glucagon secretion.
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Fig. 6. Proposed model to explain autocrine and paracrine e¡ects of
insulin in pancreatic islets based on the present ¢ndings. Under
steady-state low glucose concentration (situation I), high glucagon
levels promote a facilitative tonus upon the pancreatic L cell, while
low levels of insulin and somatostatin prevail. Once glucose levels
increase (situation II), high amounts of insulin exert a moderate in-
hibitory action upon K cells and a potent stimulatory e¡ect upon N
cells. Also, a discrete L cell positive-feedback stimulus occurs. Fi-
nally, during glucose fall (situation III), an inhibitory tonus pro-
vided by somatostatin may participate in the ¢ne tuning of insulin
secretion. Light gray arrows, stimulus; dark gray arrows, inhibition;
thick arrows, potent e¡ect; thin arrows, discrete e¡ect.
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